BRIM8: Vemurafenib in high risk melanoma patients

COMBI-AD: Dabrafenib plus trametinib in advanced melanoma

Checkmate 238: Adjuvant checkpoint therapy after melanoma resection

The role of tumour marker testing in early diagnosis

The METRIC trial of trametinib, five years on

Patient perceptions of chemotherapy side effects differ over time and treatment

Treatment choices in thyroid cancer

Clinical advances in treating colorectal cancer

RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma

RANGE trial of ramucirumab for urothelial cancer

Small node-negative breast cancers may retain aggressive characteristics

Adaptive TONIC trial of nivolumab combinations for breast cancer